伊布替尼复发慢性淋巴细胞白血病患者白血病进展及Richter转化的克隆演化
该研究对9例伊布替尼复发慢性淋巴细胞白血病(CLL)患者(其中6例发生Richter转化)的系列样本进行基因组分析,发现18p缺失伴del(17p)/TP53突变在伊布替尼治疗前见于5/9例。除BTK C481外,鉴定出位于SH2结构域的结构新颖的BTK T316A突变,并发现低等位基因频率的次要BTK克隆。Richter转化细胞为循环白血病细胞的克隆后代,但组织中的转化淋巴瘤细胞可获得与CLL白血病细胞不同的BTK突变。
要点
- 伊布替尼治疗前5/9例患者存在del(18p)伴del(17p)/TP53突变。
- 除BTK C481外,发现位于SH2结构域的结构新颖的BTK T316A突变。
- Richter转化细胞为循环白血病细胞克隆后代,但组织转化淋巴瘤细胞可获得不同BTK突变。
核心结论
- 这些结果为了解伊布替尼复发背后的克隆演化提供了见解,并提示需进一步研究具有临床应用潜力的基因组异常。
研究设计与样本
- 对9例伊布替尼复发疾病患者的系列样本进行基因组特征分析,其中6例发生Richter转化。
- 使用二代测序和单核苷酸多态性芯片评估突变、插入缺失、拷贝数异常和杂合性缺失。
主要发现
- 18p缺失(del(18p))伴del(17p)/TP53突变在伊布替尼治疗前见于5/9例患者。
- 除BTK C481外,鉴定出位于BTK SH2结构域的结构新颖的BTK T316A突变。
- 除主要BTK克隆外,还捕获到低等位基因频率的次要BTK克隆。
- TP53缺失使患者易复发,但疾病进展过程中TP53缺失的克隆大小可能缩小,而突变BTK克隆扩增。
- 在Richter转化患者中,转化细胞为循环白血病细胞的克隆后代,但继续发生演化和漂移;组织中的转化淋巴瘤细胞可获得与CLL白血病细胞不同的BTK突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment options. Mutations in BTK and PLCG2 have emerged as main mechanisms of drug resistance, but not all patients carry these mutations. Further understanding of mechanisms of resistance is urgently needed and will support rational development of new therapeutic strategies. To that end, we characterized the genomic profiles of serial samples from 9 patients with ibrutinib-relapsed disease, including 6 who had Richter transformation. Mutations, indels, copy-number aberrations, and loss of heterozygosity were assessed using next-generation sequencing and single-nucleotide polymorphism array. We found that 18p deletion (del(18p)), together with del(17p)/TP53 mutations, was present in 5 of 9 patients before ibrutinib therapy. In addition to BTKC481 , we identified BTKT316A , a structurally novel mutation located in the SH2 domain of BTK. Minor BTK clones with low allele frequencies were captured in addition to major BTK clones. Although TP53 loss predisposes patients for relapse, clone size of TP53 loss may diminish during disease progression while mutant BTK clone expands. In patients who had Richter transformation, we found that the transformed cells were clonal descendants of circulating leukemia cells but continued to undergo evolution and drifts. Surprisingly, transformed lymphoma cells in tissue may acquire a different BTK mutation from that in the CLL leukemia cells. Collectively, these results provide insights into clonal evolution underlying ibrutinib relapse and prompt further investigation on genomic abnormalities that have clinical application potential.
引用
- Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017. PMID: 29296715. doi:10.1182/bloodadvances.2016003632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。